Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation [Yahoo! Finance]
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Morgan Stanley from $48.00 to $12.00. They now have an "equal weight" rating on the stock.
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Guggenheim from $57.00 to $32.00. They now have a "buy" rating on the stock.